<DOC>
	<DOCNO>NCT00267956</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety CNTO 1275 ( ustekinumab ) patient psoriatic arthritis .</brief_summary>
	<brief_title>An Effectiveness Safety Study CNTO 1275 Patients With Active Psoriatic Arthritis</brief_title>
	<detailed_description>This study randomize ( study drug assign chance ) , double-blind ( neither physician patient know treatment patient receives ) , parallel-group ( group patient treat time ) , multicenter study evaluate effectiveness safety CNTO 1275 compare placebo treatment patient active psoriatic arthritis . Patients randomize 1:1 ratio 1 2 treatment group ( CNTO 1275 63 mg placebo ) . Patients randomly assign receive study medication Week 12 follow Week 36 monitor safety efficacy . Patients randomly assign placebo crossover receive CNTO 1275 63 mg Weeks 12 16 . Patients randomly assign CNTO 1275 receive placebo Weeks 12 16 maintain blind . The duration participation individual patient study 36 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Have active psoriatic arthritis least 6 month prior administration first study injection Have active plaque psoriasis ( defined lesion least 2 cm diameter ) , armpit , chest breast groin Women childbearing potential men must use effective method birth control measure ( eg , abstinence , oral contraceptive , intrauterine device , barrier method spermicide , surgical sterilization ) must agree continue use measure 12 month receive last injection study agent Have active arthritis despite diseasemodifying antirheumatic drug ( DMARD ) leflunomide , gold , sulfasalazine , include methotrexate ) nonsteroidal antiinflammatory agent ( NSAID ) aspirin , ibuprofen , naproxen ) therapy . DMARD therapy define take DMARD least 3 month , evidence tolerate DMARD . NSAID therapy define take NSAID least 4 week If patient use methotrexate ( MTX ) , start treatment least 3 month prior first administration study agent serious toxic side effect attributable MTX Have sign symptom suggestive active tuberculosis upon medical history , physical examination chest Xray Have receive DMARDs , methotrexate , within 4 week prior randomization visit Have use biologic within previous 3 month 5 time halflife biologic , whichever longer Have receive oral , intravenous intramuscular medications/treatments could affect psoriasis ( include , limited , oral injectable corticosteroid , retinoids , 1,25 dihydroxy vitamin D3 analogue , psoralens , sulfasalazine , hydroxyurea , fumaric acid derivative , phototherapy ) within 4 week randomization visit and/or use topical medications/treatments could affect psoriasis ( eg , corticosteroid , anthralin , calcipotriene , topical vitamin D derivative , retinoids , tazarotene , methoxsalen , trimethylpsoralens ) within 2 week randomization visit Have history chronic recurrent infectious disease , include limited chronic renal infection , chronic chest infection ( eg , bronchiectasis ) , recurrent urinary tract infection ( recurrent pyelonephritis chronic nonremitting cystitis ) , open , drain , infected skin wound ulcer Have history latent active granulomatous infection , include tuberculosis ( TB ) , histoplasmosis , coccidioidomycosis , prior screen Have current sign symptom severe , progressive , uncontrolled kidney , liver , blood , intestinal , hormonal , lung , heart , nervous , brain , psychiatric disease Have know cancer history cancer within previous 5 year ( follow exception : basal cell carcinoma squamous cell carcinoma situ skin treat , evidence recurrence )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Psoriatic arthritis</keyword>
	<keyword>CNTO 1275</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>Interleukin-23 , IL-12 , IL-23</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>